Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Risk Factors for Positive Margins in Conservative Surgery for Breast Cancer Afte...
Journal Information
Vol. 94. Issue 7.
Pages 379-384 (August - September 2016)
Visits
1639
Vol. 94. Issue 7.
Pages 379-384 (August - September 2016)
Original article
DOI: 10.1016/j.cireng.2016.08.007
Full text access
Risk Factors for Positive Margins in Conservative Surgery for Breast Cancer After Neoadjuvant Chemotherapy
Factores de riesgo de afectación de los márgenes quirúrgicos en la cirugía conservadora del cáncer de mama tras quimioterapia neoadyuvante
Visits
...
Alberto Bouzón, Benigno Acea
Corresponding author
baceneb@sergas.es

Corresponding author.
, Alejandra García, Ángela Iglesias, Joaquín Mosquera, Paz Santiago, Teresa Seoane
Unidad de Mama, Servicio de Cirugía General, Complexo Hospitalario Universitario A Coruña, La Coruña, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (3)
Table 1. Preoperative Clinical-pathological Characteristics of the 91 Patients in the Study (92 Tumors).
Table 2. Comparison of the Characteristics of the Study Patients Who Had Initially Undergone Conservative Surgery With the State of the Surgical Margins.
Table 3. Predictive Model for Positive Margins.
Show moreShow less
Abstract
Background

Breast conservative surgery after neoadjuvant chemotherapy intends to remove any residual tumor with negative margins. The purpose of this study was to analyze the preoperative clinical-pathological factors influencing the margin status after conservative surgery in breast cancer patients receiving neoadjuvant chemotherapy.

Methods

A retrospective study of 91 breast cancer patients undergoing neoadjuvant chemotherapy (92 breast lesions) during the period 2006–2013. A Cox regression analysis to identify baseline tumor characteristics associated with positive margins after breast conservative surgery was performed.

Results

Of all cases, 71 tumors were initially treated with conservative surgery after neoadjuvant chemotherapy. Pathologic exam revealed positive margins in 16 of the 71 cases (22.5%). The incidence of positive margins was significantly higher in cancers with initial size >5cm (P=.021), in cancers with low tumor grade (P=.031), and in patients with hormone receptor-positive cancer (P=.006). After a median follow-up of 45.2 months, 7 patients of the 71 treated with conservative surgery had disease recurrence (9.8%). There was no significant difference in terms of disease-free survival according to the margin status (P=.596).

Conclusions

A baseline tumor size >5cm, low tumor grade and hormone receptor-positive status increase the risk for surgical margin involvement in breast conservative surgery after neoadjuvant chemotherapy.

Keywords:
Breast cancer
Neoadjuvant chemotherapy
Conservative surgery
Positive margins
Resumen
Introducción

La cirugía conservadora de mama tras la quimioterapia neoadyuvante pretende resecar cualquier tumor residual con unos márgenes negativos. El objetivo de este estudio fue analizar los factores clínico-patológicos preoperatorios que influyen sobre el estado de los márgenes de resección tras la cirugía conservadora en pacientes con cáncer de mama tratadas con quimioterapia neoadyuvante.

Métodos

Estudio retrospectivo de 91 pacientes con cáncer de mama (92 tumores) tratadas con quimioterapia neoadyuvante durante el periodo 2006–2013. Se realizó un análisis de regresión de Cox para identificar las características basales del tumor asociadas con la afectación de los márgenes de resección tras cirugía conservadora de la mama.

Resultados

Del total de casos del estudio, 71 tumores se trataron inicialmente mediante cirugía conservadora tras la quimioterapia neoadyuvante. El examen patológico reveló afectación de márgenes en 16 de los 71 casos (22,5%). Se observó una mayor incidencia de márgenes positivos en los tumores con un tamaño inicial superior a 5cm (p=0,021), en los tumores de bajo grado histológico (p=0,031) y en los tumores con estatus positivo de los receptores hormonales (p=0,006). Tras un seguimiento medio de 45,2 meses, 7 de las 71 pacientes tratadas con cirugía conservadora presentaron recidiva de la enfermedad (9,8%). No se observaron diferencias estadísticamente significativas en la supervivencia libre de enfermedad según el estado de los márgenes quirúrgicos (p=0,596).

Conclusiones

Un tamaño tumoral basal superior a 5cm, el bajo grado tumoral y el estatus positivo de los receptores hormonales incrementan el riesgo para la afectación de los márgenes quirúrgicos en la cirugía conservadora de mama tras quimioterapia neoadyuvante.

Palabras clave:
Cáncer de mama
Quimioterapia neoadyuvante
Cirugía conservadora
Márgenes positivos
Full Text
Introduction

Breast-conserving surgery with disease-free margins in breast cancer is equivalent to mastectomy in terms of local control and survival,1 while presenting the advantage of a better psychosocial result.2

Neoadjuvant chemotherapy (NCT) is able to increase the survival rates of breast-conserving surgery without a significant increase in the percentages of local recurrence.3–5 Furthermore, complete pathologic response to treatment improves patient prognosis.6

The state of the resection margins after conservative surgery is one of the most important predictive factors for the risk of locoregional recurrence in breast cancer.7,8 Certain tumor characteristics can increase the risk for reintervention as a consequence of involved surgical margins.

The objective of this study was to identify preoperative clinical-pathological risk factors for the involvement of surgical margins after conservative surgery in patients with breast cancer treated with NCT.

MethodsStudy Population

Between October 2006 and June 2013, 91 consecutive patients with histopathological diagnosis of invasive breast cancer were treated with NCT at a single hospital. The initial diagnosis was based on mammogram and ultrasound studies, and histopathological confirmation was established by ultrasound-guided fine-needle aspiration of the lesions observed and by stereotaxis in the case of microcalcifications.

The criteria for neoadjuvant treatment were: clinical presentation in stage IIB-III, unfavorable tumor-to-breast volume ratio, or molecular profile with a high probability for complete pathologic response. Patients with distant metastasis at the time of diagnosis were excluded from the study. We conducted a retrospective review of the clinical and pathological data of the series. The study was approved by the Research Ethics Committee of our Healthcare Area (n 2015/059).

Immunohistochemistry Study

Based on the results from the initial diagnostic biopsy, the tumors were classified into 5 subtypes according to immunohistochemistry characteristics: luminal A, luminal B/HER2−, luminal B/HER2+, HER2+ and triple negative. The HER2 tumors with a score of 3+ were considered positive. If the score was 2+, the fluorescent in situ hybridization technique was used to determine whether there was amplification of the HER2 gene and to confirm or disprove positivity. The samples that did not express HER2 or had a score 1+ were considered HER2−. The cut-off point for ki-67 was set at 14% to determine whether the cell proliferation rate was high (≥14%) or low (<14%).

Axillary Lymph Node Status Prior to Neoadjuvant Chemotherapy

In all patients, axillary ultrasound was done before NCT. Selective biopsy of the sentinel lymph node was used before NCT to stage the axilla in women without clinical-radiological suspicion of axillary involvement. In patients with axillae suspicious of lymph node involvement, biopsies or ultrasound-guided FNA were used to confirm tumor infiltration, except in those cases with massive axillary lymph node involvement seen during magnetic resonance imaging (MRI).

Neoadjuvant Chemotherapy Protocol

The therapeutic protocols were selected by the Oncology Department of the Breast Pathology Unit. Initial patient evaluation included complete medical history, physical examination, complete blood work-up, chest X-ray, thoracic and abdominal computed tomography, and bone scintigraphy. A titanium clip was placed at the tumor site in all patients before initiating chemotherapy in order to be able to identify the primary tumor area during surgery. Tumor response was monitored by MRI at the start and end of systemic treatment. All patients with HER2+ tumors had trastuzumab included in their preoperative therapeutic regimen.

Breast-conserving Surgery

Tumorectomy was indicated in patients with a favorable ratio between the residual tumor volume and the breast volume. In those patients in whom severe deformity was expected, an oncoplastic pattern was indicated adapted to the breast type and tumor location. In subclinical residual lesions, a harpoon was used to mark the area of the clip. Conservative surgery was ruled out in patients with edema or cutaneous involvement, diffuse microcalcifications, multicentric residual disease or contraindication for treatment with radiotherapy. The indication for conservative surgery was considered correct when the surgical margins were disease free. If margins were positive, a second surgery was used to either extend the surgical margins or to carry out mastectomy.

Intraoperative Tumor Evaluation

The intraoperative pathological study of the surgical specimen was only done in patients with persistent lesion after NCT and consisted of a macroscopic analysis of the sample to determine the distance of the tumor from the surgical resection edges. Radiological intraoperative evaluations were routinely used in the samples marked with harpoons to identify the clip, residual calcifications or radiological abnormalities.

Histopathologic Analysis

The samples for the histopathological exam were prepared by making a series of 5mm slices of the surgical specimen, affixed in 10% neutral buffered formalin, to try to identify any lesion that corresponded with invasive carcinoma. If the tumor lesion was evident, it was completely included for morphological study with hematoxylin–eosin stain. When there was no evident tumor lesion, the marking clip was identified; the section containing the clip and the adjacent tissue sections were included in the histological study. The margins were considered negative when there was microscopic absence of invasive carcinoma on the surgical edges.

Statistical Analysis

A descriptive analysis was completed of the variables included in the study. The quantitative variables were expressed as means and standard deviation, and the qualitative variables were expressed as absolute value and percentage with the estimation of their 95% confidence interval. The association of qualitative variables was estimated by means of the Chi-squared or Fisher's exact tests, as necessary. The comparison of quantitative variables was done using the non-parametric Mann–Whitney U test. A bivariate and multivariate analysis was conducted using logistic regression models of a series of clinical-pathological parameters to predict the involvement of the surgical margins after breast-conserving surgery. The multivariate analysis included the variables that were significantly associated with the state of the surgical margins after the bivariate analysis. The follow-up time and disease-free survival (DFS) of each patient were determined by the difference between the date of surgery and date of recurrence, death or end of study. DFS was analyzed by estimating Kaplan–Meier curves and their comparison by means of the log-rank test.

ResultsClinical-pathological Characteristics of the Patients

The baseline clinical-pathological characteristics of the study patients are shown in Table 1. A total of 91 women with invasive breast cancer received NCT and, afterwards, excision of the primary tumor was indicated. A total of 92 tumors were analyzed, as one patient was diagnosed with bilateral breast cancer.4 Mean patient age at the time of diagnosis was 47.2 years (range: 31–75). Mean baseline tumor size (BTS), defined by MRI, was 3.9cm. The majority of the tumors were T2 (75%) and T3 (54.4%). The biopsies revealed 85 cases of ductal carcinoma (92.4%) and 7 cases of lobular carcinoma (7.6%). Hormone receptors (HR) were negative in 32.6% of the cases, and there was no evidence of overexpression of the HER2 gene in 72.8% of the tumors.

Table 1.

Preoperative Clinical-pathological Characteristics of the 91 Patients in the Study (92 Tumors).

Age (years)a  47.2 (10.1)
Baseline tumor size (cm)a  3.9 (1.9)
Clinical tumor stage     
  T1  7 (7.6) 
  T2  69 (75.0) 
  T3  13 (14.1) 
  T4  3 (3.3) 
Histological subtype     
  Ductal  85 (92.4) 
  Lobular  7 (7.6) 
Histological grade     
  G1  9 (10.0) 
  G2  32 (35.6) 
  G3  49 (54.4) 
  NA 
Ki-67 expression     
  <14%  12 (13.5) 
  ≥14%  77 (86.5) 
  NA 
Hormone receptors     
  Positive  60 (65.2) 
  Negative  32 (34.8) 
HER2     
  Positive  25 (27.2) 
  Negative  67 (72.8) 
Molecular phenotype     
  Luminal A  11 (12.0) 
  Luminal B/HER2−  35 (38.0) 
  Luminal B/HER2+  16 (17.4) 
  HER2+  9 (9.8) 
  Triple negative  21 (22.8) 
Axillary status prior to NCT     
  Positive  76 (82.6) 
  Negative  16 (17.4) 

NA: not available; NCT: neoadjuvant chemotherapy.

a

Age and tumor size are expressed as mean and standard deviation. The remaining variables are expressed as number and percentage.

Out of the 92 tumors included in the study, 76 (82.6%) presented axillary lymph node disease at the time of diagnosis. Histopathologic confirmation was obtained in 62 (81.6%) of these cases (46 cases by core needle biopsy or fine-needle aspiration, and 16 cases by SLNB done before NCT), while in 14 cases (18.4%), MRI revealed massive axillary lymph node involvement. In 16 tumors (17.4%), no axillary clinical-radiological involvement was detected at the time of diagnosis.

The distribution of the different primary systemic therapies was as follows: 60 patients (65.9%) received a regimen combining anthracycline and taxane; 25 patients (27.5%) received a regime that included trastuzumab, in addition to the combination of anthracycline and taxane; 6 patients (6.6%) received a regime containing taxane (nab-paclitaxel). Preoperative MRI verified a reduction in tumor size after NCT compared to the initial MRI in 88% of cases (81/92). We observed complete tumor remission in 38 cases (41.3%), partial remission in 43 cases (46.7%), stable disease in 10 cases (10.9%) and progressive disease in one single case (1.1%).

After NCT, 21 cases (21.8%) were treated with mastectomy (one patient with bilateral mastectomy) and breast-conserving surgery was attempted in 71 cases (77.2%). From this last group, 16 patients (22.5%) were reoperated on due to the involvement of the surgical margins; extended breast-conserving surgery was possible in 13 cases, and mastectomy was performed in 3 patients. The final percentages of breast preservation and mastectomy were 73.9 and 26.1%, respectively. The pathology study revealed the presence of invasive residual tumor in 3 of the 16 cases reoperated (18.7%).

Bivariate and Multivariate Analyses for Predicting the State of the Surgical Margins

Table 2 compares the characteristics of the 71 patients initially treated by conservative surgery after NCT versus the state of the surgical margins. In the bivariate analysis, significant differences were observed in BTS variables, tumor histology grade and HR status. Lesions with a BTS higher than 5cm had a greater incidence of positive margins compared to the tumors with a baseline size equal to or less than 5cm (66.7 vs 18.5%; P=.021). The incidence of positive margins was also greater in low-grade tumors than in high-grade tumors (34.4 vs 12.8%; P=.031). As for HR status, involvement of the margins was observed in 32.6% of the tumors with positive HR, versus 4% of the tumors with negative HR (P=.006). No significant differences were found regarding the state of the margins for the variables age, histology type, ki-67 and status of the HER2 gene.

Table 2.

Comparison of the Characteristics of the Study Patients Who Had Initially Undergone Conservative Surgery With the State of the Surgical Margins.

Characteristics  Positive margins (n=16)  Negative margins (n=55)   
  n (%)  n (%)  P 
Age (years)      .391 
≤45  5 (16.1)  26 (83.9)   
>45  11 (27.5)  29 (72.5)   
BTS (cm)      .021 
≤5  12 (18.5)  53 (81.5)   
>5  4 (66.7)  2 (33.3)   
Histologic type      .123 
Ductal  13 (20)  52 (80)   
Lobular  3 (50)  3 (50)   
Histology grade      .031 
Low (1 or 2)  11 (34.4)  21 (65.6)   
High (3)  5 (12.8)  34 (87.2)   
Ki-67expression      .065 
Low (<14%)  4 (50)  4 (50)   
High (≥14%)  11 (18.3)  49 (81.7)   
HR status      .006 
Positive  15 (32.6)  31 (67.4)   
Negative  1 (4)  24 (96)   
HER2 status      1.000 
Positive  4 (22.2)  14 (77.8)   
Negative  12 (22.6)  41 (77.4)   
Pre-NCT axillary status      .471 
Positive  12 (20.7)  46 (79.3)   
Negative  4 (30.8)  9 (69.2)   
Tumor response (MRI)      .572 
Complete  6 (19.4)  25 (80.6)   
Incomplete  10 (25)  30 (75)   

HER2: human epidermal growth factor receptor 2; NCT: neoadjuvant chemotherapy; HR: hormone receptors; MRI: magnetic resonance imaging; BTS: baseline tumor size.

The multivariate analysis revealed that the only independent variables associated with positive resection margins were HR status and BTS (Table 3). The risk for involvement of the surgical margins was 14 times greater in the tumors with positive HR than in the tumors with negative HR (P=.038), and this risk is 16 times greater in tumors with an initial size greater than 5cm than in the tumors with an initial size equal to or less than 5cm (P=.029).

Table 3.

Predictive Model for Positive Margins.

Variables  OR  95% CI  P 
HR +  14.36  1.15–178.76  .038 
BTS >5cm  15.94  1.32–192.37  .029 
Low HG  1.49  0.39–5.78  .560 

HG: histology grade; CI: confidence interval; OR: odds ratio; HR: hormone receptors; BTS: baseline tumor size.

Disease-free Survival

After a mean follow-up of 45.2 months, 13 patients (14.3%) presented disease recurrence (locoregional or systemic). DFS after 2 and 5 years was 88.9 and 83%, respectively. In the group of patients who initially underwent conservative surgery (n=71), 7 patients presented disease recurrence (9.8%): 2 ipsilateral breast tumor recurrence (IBTR) (2.8%), and 5 distant metastases (7%). When we compared the DFS according to the state of the surgical margins, no statistically significant differences were observed (P=.596) (Fig. 1). The incidence of IBTR was 1.8% in women with negative margins and 6.3% in women with positive margins (P=.402).

Fig. 1.

Kaplan–Meier curves for disease-free survival according to the state of the surgical margins after breast-conserving surgery in patients who received neoadjuvant chemotherapy.

(0.09MB).
Discussion

NCT has the capability to increase breast preservation percentages in patients with operable breast cancer who are initially candidates for mastectomy. Conversion rates to conservative surgery have been reported to range between 23 and 46%.3,9–11

The use of a series of clinical-pathological characteristics as predictive factors for locoregional recurrence can improve the risk stratification for recurrence in patients treated with NCT and breast-conserving surgery.12 The presence of positive margins increases the incidence of IBTR, with no significant impact on overall survival.13,14

The evaluation of surgical margins is more complicated after NCT, which is due to the variability in tumor regression patterns.15 Nonetheless, a greater incidence of positive margins has not been observed in conservative surgery after NCT compared to primary conservative surgery.16 The incidence of positive margins in our series (22.5%) is similar to the 21% reported in other studies for patients treated with NCT.16,17

Oncoplastic resection and segmentation can decrease the risk for reintervention. Losken et al.18 demonstrated a lower incidence of positive margins in oncoplastic surgery compared to classical breast-conserving surgery (12.2 vs 20.6%). Our better understanding of the characteristics of each breast region provides for improved oncologic safety and esthetic results in conservative surgical planning.19

Risk factors associated with a higher incidence of positive margins include: the lobular histological type, positive HR status and a large BTS.16,20–22 In the context of NCT, there are also studies that report a greater incidence of tumor involvement of the margins in lobular carcinomas versus ductal carcinomas.23,24

In our study patients initially treated with breast-conserving surgery, a significant association was observed between the state of the surgical margins and BTS, tumor grade and HR status. The tumors with positive HR, low-grade tumors and lesions with a BTS>5cm presented higher rates of margin involvement. In spite of observing a greater incidence of positive margins in the lobular carcinomas than in the ductal carcinomas (50 vs 20%), no significant association was observed with the histology type variable, which is possibly due to the small sample size of lobular carcinomas in our study.

In our logistic regression model, BTS and HR status were the only independent predictive factors of involvement of the surgical margins. The risk for presenting positive margins was 16 times greater in lesions with a BTS>5cm compared to the lesions with a BTS≤5cm and 14 times greater in luminal tumors compared to non-luminal tumors. It has been demonstrated that large lesions and luminal tumors have a poorer response to NCT.11,15 Furthermore, it is relatively frequent that luminal tumors present as diffuse lesions with a non-concentric tumor regression pattern after NCT. These circumstances make it complicated to perform resections with negative margins.

Finally, when we analyzed DFS according to the state of the surgical margins, no significant differences were found. The IBTR incidence of 2.8% is low (only 2 cases). Therefore, there were no significant differences when comparing the incidence of IBTR according to the state of the margins, even though this was greater in the group of women with positive margins compared to the group with negative margins (6.3 vs 1.8%). These 2 patients presented low-grade invasive ductal carcinoma with subtype luminal A and partial radiological response to NCT.

This study has several limitations. The current molecular classification of breast cancer sets the cut-off point for ki-67 expression at 20% to define high and low grades.25 The study did not include radiological parameters among the risk factors for margin involvement. Furthermore, only 7 cases with lobular carcinoma were registered.

In conclusion, this study shows that, although it is feasible to perform conservative surgery in the majority of patients with operable breast cancer treated with NCT, the probability to achieve negative margins is lower in luminal tumors with low histologic grade and an initial tumor size greater than 5cm.

Conflict of Interests

The authors have no conflict of interests to declare.

References
[1]
B. Fisher, S. Anderson, J. Bryant, R.G. Margolese, M. Deutsch, E.R. Fisher, et al.
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy plus irradiation for the treatment of invasive breast cancer.
N Engl J Med, 347 (2002), pp. 1233-1241
[2]
L. Irwig, A. Bennett.
Quality of life after breast conservation or mastectomy: a systematic review.
Aust N Z J Surg, 67 (1997), pp. 750-754
[3]
J.A. Van der Hage, C.J. van de Velde, J.P. Julien, M. Tubiana-Hulin, C. Vandervelden, L. Duchateau.
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902.
J Clin Oncol, 19 (2001), pp. 4224-4237
[4]
N. Wolmark, J. Wang, E. Mamounas, J. Bryant, B. Fisher.
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.
J Natl Cancer Inst Monogr, 30 (2001), pp. 96-102
[5]
L. Gianni, J. Baselga, W. Eirmann, V. Guillem Porta, V. Semiglazov, A. Lluch, et al.
European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracilo (CMF).
J Clin Oncol, 23 (2005), pp. 7s
[6]
H.M. Kuerer, L.A. Newman, T.L. Smith, F.C. Ames, K.K. Hunt, K. Dhingra, et al.
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
J Clin Oncol, 17 (1999), pp. 460-469
[7]
T.L. Huston, R.M. Simmons.
Locally recurrent breast cancer after conservation therapy.
Am J Surg, 189 (2005), pp. 229-235
[8]
N. Houssami, P. Macaskill, M.L. Marinovich, J.M. Dixon, L. Irwig, M.E. Brennan, et al.
Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy.
Eur J Cancer, 46 (2010), pp. 3219-3232
[9]
L.A. Newman, A.U. Buzdar, S.E. Singletary, H.M. Kuerer, T. Buchholz, F.C. Ames, et al.
A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.
Ann Surg Oncol, 9 (2002), pp. 228-234
[10]
P.M. Spanheimer.
The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer.
[11]
B. Fisher, A. Brown, E. Mamounas, S. Wieand, A. Robidoux, R.G. Margolese, et al.
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
J Clin Oncol, 15 (1997), pp. 2483-2493
[12]
C.L. Akay, F. Meric-Bernstam, K.K. Hunt, E.G. Grubbs, I. Bedrosian, S.L. Tucker, et al.
Evaluation of the MD Anderson prognostic index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy.
Ann Surg Oncol, 19 (2012), pp. 901-907
[13]
M.S. Moran, S.J. Schnitt, A.E. Giuliano, J.R. Harris, S.A. Khan, J. Horton, et al.
Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.
Int J Radiation Oncol Biol Phys, 88 (2014), pp. 553-564
[14]
O. Gentilini, M. Intra, S. Gandini, G. Peruzzotti, E. Winnikow, A. Luini, et al.
Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome.
J Surg Oncol, 94 (2006), pp. 375-379
[15]
I. Sachelarie, M.L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, R.H. Blum.
Primary systemic therapy of breast cancer.
Oncologist, 11 (2006), pp. 574-589
[16]
G. Soucy, J. Bélanger, G. Leblanc, L. Sideris, P. Drolet, A. Mitchell, et al.
Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact?.
J Am Coll Surg, 206 (2008), pp. 1116-1121
[17]
S. Loibl, G. von Minckwitz, G. Raab, J.U. Blohmer, S. Dan Costa, B. Gerber, et al.
Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.
Ann Surg Oncol, 13 (2006), pp. 1434-1442
[18]
A. Losken, C.S. Dugal, T.M. Styblo, G.W. Carlson.
A meta-analysis comparing breast conservation therapy alone to the oncoplastic technique.
Ann Plast Surg, 72 (2014), pp. 145-149
[19]
B. Acea.
Breast segments: a model for the prevention of deformities in conservative surgery for breast cancer.
[20]
S.E. Singletary.
Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy.
Am J Surg, 184 (2002), pp. 383-393
[21]
A.B. Chapgar, R.C. Martin, L.J. Hagendoorn, C. Chao, K.M. McMasters.
Lumpectomy margins are affected by tumor size and histologic subtype but not by biopsy technique.
Am J Surg, 188 (2004), pp. 399-402
[22]
M.C. Smitt, K. Horst.
Association of clinical and pathologic variables with lumpectomy surgical margin status after preoperative diagnosis or excisional biopsy of invasive breast cancer.
Ann Surg Oncol, 14 (2007), pp. 1040-1044
[23]
V.F. Cocquyt, P.N. Blondeel, H.T. Depypere, M.M. Praet, V.R. Schelfhout, O.E. Silva, et al.
Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
Eur J Surg Oncol, 29 (2003), pp. 361-367
[24]
M. Tubiana-Hulin, D. Stevens, S. Lasry, J.M. Guinebretière, L. Bouita, C. Cohen-Solal, et al.
Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution.
Ann Oncol, 17 (2006), pp. 1228-1233
[25]
A. Goldhirsch, E.P. Winer, A.S. Coates, R.D. Gelber, M. Piccart-Gebhart, B. Thürlimann, et al.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013.
Ann Oncol, 24 (2013), pp. 2206-2223

Please cite this article as: Bouzón A, Acea B, García A, Iglesias Á, Mosquera J, Santiago P, et al. Factores de riesgo de afectación de los márgenes quirúrgicos en la cirugía conservadora del cáncer de mama tras quimioterapia neoadyuvante. Cir Esp. 2016;94:379–384.

Copyright © 2016. AEC
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos